Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread

Inclusion Criteria: * Women with histologically proven invasive carcinoma of the uterine cervix and para aortic lymphadenopathy determined by either a positive positron emission tomography with 2-deoxy-2-\[fluorine-18\]fluoro- D-glucose integrated with computed tomography or if negative positron emission tomography computed tomography based on histological examination of paraaortic lymph node dissection. * Performance status Eastern Cooperative Oncology Group 0-2 * Stage International Federation of Gynecology and Obstetrics IB1 to IVA at diagnosis with para-aortic lymph node involvement * Adenocarcinoma or squamous cell carcinoma or adenosquamous carcinoma * Adequate renal function (creatinine clearance ≥60 mL/min) * Adequate hepatic function (bilirubin \<1.5 times normal and Serum Glutamooxaloacetate Transferase \< 3 times normal) * Adequate hematopoietic function Platelet count \> 100x10 9/l and Absolute neutrophil count \> 1.5X10 9/l) * Written Informed consent for participation Exclusion Criteria: * Stage Federation of Gynecology and Obstetrics IVB at diagnosis * Others histologies than adenocarcinoma, squamous cell carcinoma and adenosquamous carcinoma. * Women who receive any prior chemotherapy for her cervical cancer * Pregnant or lactating women * Prior ( within the last 5 years) malignancies other than non-melanoma skin cancer * Inadequate renal, hepatic or hematopoietic function (Cf previously) * Cardiovascular pathology New York Heart Association II or more * Pre-existing Peripheral neuropathy Common toxicity Criteria grade ≥ 2